Key regulators of apoptosis execution as biomarker candidates in melanoma

Resistance to apoptosis is frequently detected in malignant melanoma, a skin cancer with rapidly growing incidence rates. Apoptosis resistance may develop with disease progression and may be associated with the poor responsiveness of metastatic melanoma to apoptosis-inducing treatments, such as geno...

Full description

Saved in:
Bibliographic Details
Published in:Molecular & cellular oncology 2014-09, Vol.1 (3), p.e964037-e964037
Main Authors: Charles, Emilie M, Rehm, Markus
Format: Article
Language:English
Subjects:
APAF-1
apoptosis
biomarker
caspases
IAP antagonist
melanoma
Review
XIAP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83
cites cdi_FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83
container_end_page e964037
container_issue 3
container_start_page e964037
container_title Molecular & cellular oncology
container_volume 1
creator Charles, Emilie M
Rehm, Markus
description Resistance to apoptosis is frequently detected in malignant melanoma, a skin cancer with rapidly growing incidence rates. Apoptosis resistance may develop with disease progression and may be associated with the poor responsiveness of metastatic melanoma to apoptosis-inducing treatments, such as genotoxic chemotherapy and radiotherapy. Likewise, the efficacy of novel treatment options (targeted kinase inhibitors and immunotherapeutics) that indirectly lead to cell death may depend on the susceptibility of melanoma to apoptosis. At its core, apoptosis execution is regulated by the interplay between a comparatively small number of pro- and anti-apoptotic proteins, and consequently numerous studies have investigated the potential of these players as biomarker candidates. Here, we provide a comprehensive overview of biomarker discovery studies focusing on key regulators of apoptosis execution, critically review the findings of these studies, and outline strategies that address current limitations and challenges in exploiting regulators of apoptosis execution as prognostic or predictive biomarkers in melanoma.
doi_str_mv 10.4161/23723548.2014.964037
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4904965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1797873081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83</originalsourceid><addsrcrecordid>eNp9UU1P3DAQtaqiLgL-QYV87GUXf9u5tKoQLahIXOBsjZMJNU3irZ0A--_JamFFLz3NaObNezPzCPnM2Upxw8-EtEJq5VaCcbWqjGLSfiCH2_JSam0-vssX5KSUB8YY18IJrj-RhbCSOanlIbn6hRua8X7qYEy50NRSWKf1mEosFJ-xnsaYBgqFhph6yH8w0xqGJjYwYqFxoD12MMytY3LQQlfw5DUekbsfF7fnl8vrm59X59-vl7UyalwqDqzmoIQRsmmdFNaYRoEz2gZUrQ4OteUyCBeCsxiCaIIGVwXecls1Th6Rrzve9RR6bGocxgydX-c4r7fxCaL_tzPE3_4-PXpVMVUZPRN8eSXI6e-EZfR9LDV28xmYpuJnGeu2D-IzVO2gdU6lZGz3Mpz5rRH-zQi_NcLvjJjHTt-vuB96e_sM-LYDxKFNuYenlLvGj7DpUm4zDHUsXv5X4gW2_Zil</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797873081</pqid></control><display><type>article</type><title>Key regulators of apoptosis execution as biomarker candidates in melanoma</title><source>PubMed</source><creator>Charles, Emilie M ; Rehm, Markus</creator><creatorcontrib>Charles, Emilie M ; Rehm, Markus</creatorcontrib><description>Resistance to apoptosis is frequently detected in malignant melanoma, a skin cancer with rapidly growing incidence rates. Apoptosis resistance may develop with disease progression and may be associated with the poor responsiveness of metastatic melanoma to apoptosis-inducing treatments, such as genotoxic chemotherapy and radiotherapy. Likewise, the efficacy of novel treatment options (targeted kinase inhibitors and immunotherapeutics) that indirectly lead to cell death may depend on the susceptibility of melanoma to apoptosis. At its core, apoptosis execution is regulated by the interplay between a comparatively small number of pro- and anti-apoptotic proteins, and consequently numerous studies have investigated the potential of these players as biomarker candidates. Here, we provide a comprehensive overview of biomarker discovery studies focusing on key regulators of apoptosis execution, critically review the findings of these studies, and outline strategies that address current limitations and challenges in exploiting regulators of apoptosis execution as prognostic or predictive biomarkers in melanoma.</description><identifier>ISSN: 2372-3556</identifier><identifier>EISSN: 2372-3556</identifier><identifier>DOI: 10.4161/23723548.2014.964037</identifier><identifier>PMID: 27308353</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>APAF-1 ; apoptosis ; biomarker ; caspases ; IAP antagonist ; melanoma ; Review ; XIAP</subject><ispartof>Molecular &amp; cellular oncology, 2014-09, Vol.1 (3), p.e964037-e964037</ispartof><rights>2014 The Author(s). 2014 Taylor &amp; Francis Group, LLC 2014</rights><rights>2014 The Author(s). 2014 Taylor &amp; Francis Group, LLC 2014 The Author(s)</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83</citedby><cites>FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904965/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904965/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27308353$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Charles, Emilie M</creatorcontrib><creatorcontrib>Rehm, Markus</creatorcontrib><title>Key regulators of apoptosis execution as biomarker candidates in melanoma</title><title>Molecular &amp; cellular oncology</title><addtitle>Mol Cell Oncol</addtitle><description>Resistance to apoptosis is frequently detected in malignant melanoma, a skin cancer with rapidly growing incidence rates. Apoptosis resistance may develop with disease progression and may be associated with the poor responsiveness of metastatic melanoma to apoptosis-inducing treatments, such as genotoxic chemotherapy and radiotherapy. Likewise, the efficacy of novel treatment options (targeted kinase inhibitors and immunotherapeutics) that indirectly lead to cell death may depend on the susceptibility of melanoma to apoptosis. At its core, apoptosis execution is regulated by the interplay between a comparatively small number of pro- and anti-apoptotic proteins, and consequently numerous studies have investigated the potential of these players as biomarker candidates. Here, we provide a comprehensive overview of biomarker discovery studies focusing on key regulators of apoptosis execution, critically review the findings of these studies, and outline strategies that address current limitations and challenges in exploiting regulators of apoptosis execution as prognostic or predictive biomarkers in melanoma.</description><subject>APAF-1</subject><subject>apoptosis</subject><subject>biomarker</subject><subject>caspases</subject><subject>IAP antagonist</subject><subject>melanoma</subject><subject>Review</subject><subject>XIAP</subject><issn>2372-3556</issn><issn>2372-3556</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9UU1P3DAQtaqiLgL-QYV87GUXf9u5tKoQLahIXOBsjZMJNU3irZ0A--_JamFFLz3NaObNezPzCPnM2Upxw8-EtEJq5VaCcbWqjGLSfiCH2_JSam0-vssX5KSUB8YY18IJrj-RhbCSOanlIbn6hRua8X7qYEy50NRSWKf1mEosFJ-xnsaYBgqFhph6yH8w0xqGJjYwYqFxoD12MMytY3LQQlfw5DUekbsfF7fnl8vrm59X59-vl7UyalwqDqzmoIQRsmmdFNaYRoEz2gZUrQ4OteUyCBeCsxiCaIIGVwXecls1Th6Rrzve9RR6bGocxgydX-c4r7fxCaL_tzPE3_4-PXpVMVUZPRN8eSXI6e-EZfR9LDV28xmYpuJnGeu2D-IzVO2gdU6lZGz3Mpz5rRH-zQi_NcLvjJjHTt-vuB96e_sM-LYDxKFNuYenlLvGj7DpUm4zDHUsXv5X4gW2_Zil</recordid><startdate>20140915</startdate><enddate>20140915</enddate><creator>Charles, Emilie M</creator><creator>Rehm, Markus</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140915</creationdate><title>Key regulators of apoptosis execution as biomarker candidates in melanoma</title><author>Charles, Emilie M ; Rehm, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>APAF-1</topic><topic>apoptosis</topic><topic>biomarker</topic><topic>caspases</topic><topic>IAP antagonist</topic><topic>melanoma</topic><topic>Review</topic><topic>XIAP</topic><toplevel>online_resources</toplevel><creatorcontrib>Charles, Emilie M</creatorcontrib><creatorcontrib>Rehm, Markus</creatorcontrib><collection>Taylor &amp; Francis Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular &amp; cellular oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Charles, Emilie M</au><au>Rehm, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Key regulators of apoptosis execution as biomarker candidates in melanoma</atitle><jtitle>Molecular &amp; cellular oncology</jtitle><addtitle>Mol Cell Oncol</addtitle><date>2014-09-15</date><risdate>2014</risdate><volume>1</volume><issue>3</issue><spage>e964037</spage><epage>e964037</epage><pages>e964037-e964037</pages><issn>2372-3556</issn><eissn>2372-3556</eissn><abstract>Resistance to apoptosis is frequently detected in malignant melanoma, a skin cancer with rapidly growing incidence rates. Apoptosis resistance may develop with disease progression and may be associated with the poor responsiveness of metastatic melanoma to apoptosis-inducing treatments, such as genotoxic chemotherapy and radiotherapy. Likewise, the efficacy of novel treatment options (targeted kinase inhibitors and immunotherapeutics) that indirectly lead to cell death may depend on the susceptibility of melanoma to apoptosis. At its core, apoptosis execution is regulated by the interplay between a comparatively small number of pro- and anti-apoptotic proteins, and consequently numerous studies have investigated the potential of these players as biomarker candidates. Here, we provide a comprehensive overview of biomarker discovery studies focusing on key regulators of apoptosis execution, critically review the findings of these studies, and outline strategies that address current limitations and challenges in exploiting regulators of apoptosis execution as prognostic or predictive biomarkers in melanoma.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>27308353</pmid><doi>10.4161/23723548.2014.964037</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2372-3556
ispartof Molecular & cellular oncology, 2014-09, Vol.1 (3), p.e964037-e964037
issn 2372-3556
2372-3556
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4904965
source PubMed
subjects APAF-1
apoptosis
biomarker
caspases
IAP antagonist
melanoma
Review
XIAP
title Key regulators of apoptosis execution as biomarker candidates in melanoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T21%3A51%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Key%20regulators%20of%20apoptosis%20execution%20as%20biomarker%20candidates%20in%20melanoma&rft.jtitle=Molecular%20&%20cellular%20oncology&rft.au=Charles,%20Emilie%20M&rft.date=2014-09-15&rft.volume=1&rft.issue=3&rft.spage=e964037&rft.epage=e964037&rft.pages=e964037-e964037&rft.issn=2372-3556&rft.eissn=2372-3556&rft_id=info:doi/10.4161/23723548.2014.964037&rft_dat=%3Cproquest_pubme%3E1797873081%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-41a0c1a42623df832766d4a8657be4f5b8e5713b28bb87ebb2db5a89b1f179d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1797873081&rft_id=info:pmid/27308353&rfr_iscdi=true